NAD+ Oral Supplement Pilot Intervention in Adult Females
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 53
- 试验地点
- 2
- 主要终点
- Neurocognition
研究概览
简要总结
The goal of this clinical trial is to learn whether Nicotinamide adenine dinucleotide (NAD+) can influence cognition and biomarkers in healthy, cognitively intact women aged 40-80. The main questions it aims to answer are:
Will cognitive functioning change in response to NAD+? Will inflammatory markers and serum indicators of neurodegeneration change in response to NAD+? Researchers will compare individuals receiving NAD+ to those receiving placebo to see if the results differ.
Participants will:
Complete an online questionnaire, Visit the lab for computerized cognitive testing and a blood draw, Take NAD+ or a placebo every day for 4 weeks, Visit the lab for computerized cognitive testing and a blood draw
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Identify as Female
- •Have a BMI of 18.5 or above
- •Must be able to swallow tablets
排除标准
- •Those who are pregnant, breastfeeding, or taking hormone medication
研究组 & 干预措施
Pre-testing prior to intervention
Prior to receiving the supplement, either Nicotinamide adenine dinucleotide or the placebo, participants will undergo cognitive testing and a blood draw.
Post-testing after intervention
After receiving the supplement, either Nicotinamide adenine dinucleotide or the placebo, participants will undergo cognitive testing and a blood draw.
Intervention
For four weeks, the participant will consume an oral supplement, either Nicotinamide adenine dinucleotide or a placebo.
干预措施: Treatment (Dietary Supplement)
Intervention
For four weeks, the participant will consume an oral supplement, either Nicotinamide adenine dinucleotide or a placebo.
干预措施: Placebo (Other)
结局指标
主要结局
Neurocognition
时间窗: four weeks
NIH Toolkit Cognition Battery, Automated Neuropsychological Assessment Metrics
Neurodegenerative disease panel
时间窗: four weeks
BDNF, Cathespin D, MPO, PAI-1 (total), PDGF-AA, PDGF-AB/BB, RANTES, slCAM-1, sNCAM, sVCAM-1
Markers of systemic inflammation
时间窗: four weeks
GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-23, TNFα
次要结局
未报告次要终点